|Dr. George A. Scangos||Pres, CEO & Director||994.88k||N/A||1948|
|Mr. Howard Horn||CFO & Sec.||681.83k||N/A||1978|
|Dr. Herbert W. Virgin IV||Exec. VP of Research & Chief Scientific Officer||1.11M||5.12M||1956|
|Mr. Steven J. Rice||Chief Admin. Officer||698.62k||N/A||1960|
|Dr. Klaus Frueh Ph.D.||Co-Founder & Scientific Advisor||N/A||N/A||1960|
|Dr. Lawrence Corey||Co-Founder & Scientific Advisor||N/A||N/A||N/A|
|Dr. Louis J. Picker M.D.||Co-Founder & Scientific Advisor||N/A||N/A||N/A|
|Dr. Aine M. Hanly Ph.D.||Chief Technology Officer||N/A||N/A||1970|
|Dr. Neera Dahiya Ravindran M.D., MBA||VP and Head of Investor Relations & Strategic Communications||N/A||N/A||N/A|
|Ms. Irene Pleasure J.D., Ph.D.||Sr. VP & Gen. Counsel||N/A||N/A||N/A|
Vir Biotechnology, Inc., a clinical-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; VIR-1111 for the prevention of human immunodeficiency virus; and VIR-2020 for the prevention of tuberculosis. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; a collaboration, license, and option agreement with Visterra, Inc.; license agreements with The Rockefeller University and MedImmune, Inc.; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with Generation Bio., as well as GlaxoSmithKline Intellectual Property Development Limited, GlaxoSmithKline Biologicals SA., and Alnylam Pharmaceuticals, Inc. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies for potential COVID-19 treatment; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. Vir Biotechnology, Inc. was founded in 2016 and is headquartered in San Francisco, California.
Vir Biotechnology, Inc.’s ISS governance QualityScore as of 26 September 2021 is 8. The pillar scores are Audit: 5; Board: 6; Shareholder rights: 8; Compensation: 9.